Press Releases Galmed Pharmaceuticals Ltd.

Equities

GLMD

IL0011313900

Market Closed - Nasdaq Other stock markets 02:00:00 11/05/2024 am IST			5-day change	1st Jan Change
0.3983 ^USD	-4.02%		+2.81%	-12.46%

04/04	Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
15/03	Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis	15/03	PR
Galmed Pharmaceuticals : Consolidated Financial Statements - Form 6-K	23/11	PU
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study	21/11	PR
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification	25/23/25	AQ
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification	23/23/23	PR
Galmed Pharmaceuticals: Q2 Earnings Snapshot	10/23/10	AQ
Galmed Pharmaceuticals : 16 Tiomkin St. Tel Aviv 6578317, Israel - Form 6-K	10/23/10	PU
Galmed Pharmaceuticals : Securities Purchase Agreement - Form 6-K	18/23/18	PU
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering	17/23/17	AQ
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering	14/23/14	PR
Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC	10/23/10	PR
Galmed Pharmaceuticals: Q1 Earnings Snapshot	01/23/01	AQ
Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments	01/23/01	PR
Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt	08/23/08	PR
Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol	04/23/04	PR
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement	15/22/15	PR
Galmed Pharmaceuticals: Q3 Earnings Snapshot	17/22/17	AQ
Galmed Pharmaceuticals: Q2 Earnings Snapshot	04/22/04	AQ
Galmed Pharmaceuticals : Provides Business Update and Reports Second Quarter 2022 Financial Results - Form 6-K	04/22/04	PU
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results	04/22/04	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Galmed Pharmaceuticals Ltd.

Equities

GLMD

IL0011313900

Press Releases

Filters